|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
WO2000058313A1
(en)
|
1999-03-29 |
2000-10-05 |
Neurogen Corporation |
4-substituted quinoline derivatives as gaba receptor ligands
|
|
US6855715B1
(en)
|
1999-06-14 |
2005-02-15 |
Eli Lilly And Company |
Serine protease inhibitors
|
|
KR100681724B1
(ko)
|
1999-10-19 |
2007-02-28 |
머크 앤드 캄파니 인코포레이티드 |
티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
CA2424689A1
(en)
|
2000-10-17 |
2002-04-25 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
US7169788B2
(en)
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US20060111368A1
(en)
*
|
2002-06-26 |
2006-05-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Phosphodiesterase inhibitor
|
|
ATE477268T1
(de)
|
2003-01-28 |
2010-08-15 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur behandlung von magen-darm- störungen
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW201018662A
(en)
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
US20090118135A1
(en)
*
|
2007-06-08 |
2009-05-07 |
The Burnham Institute |
Methods and compounds for regulating apoptosis
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
KR20170091783A
(ko)
|
2008-12-31 |
2017-08-09 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
AU2013304812B2
(en)
|
2012-08-21 |
2016-06-09 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
SMT201900386T1
(it)
|
2013-04-12 |
2019-09-09 |
Ardelyx Inc |
Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
|
MX387903B
(es)
*
|
2014-07-08 |
2025-03-19 |
Corteva Agriscience Llc |
Proceso para la preparacion de acidos 3-hidroxipicolinicos.
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
JP2020505333A
(ja)
|
2017-01-09 |
2020-02-20 |
アルデリックス， インコーポレイテッド |
Ｎｈｅ媒介性アンチポートの阻害薬
|
|
AU2018205400C1
(en)
|
2017-01-09 |
2026-01-15 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
US20210401821A1
(en)
*
|
2018-11-15 |
2021-12-30 |
Kyushu University, National University Corporation |
Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease
|